Thymic Tumor Clinical Trials (April 2026): 33 Recruiting Interventional Studies

Last updated: April 18, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

First-Line / Newly Diagnosed

For previously untreated advanced or unresectable thymic tumors:

• NCT05832827 - Carboplatin/Paclitaxel + Lenvatinib + Pembrolizumab (first-line)
• NCT06730308 - Glucocorticoids + concurrent chemoradiotherapy for unresectable thymoma

Second-Line / Refractory

After progression on first-line therapy:

• NCT06838910 - Tislelizumab + Anlotinib (second-line)
• NCT05104736 - PT-112 novel agent
• NCT03295227 - Pembrolizumab monotherapy (unresectable)

Adjuvant / Post-Surgery

After surgical resection to reduce recurrence:

• NCT02633553 - Adjuvant radiotherapy for stage II/III thymoma after complete resection
• NCT06311955 - Postoperative carbon ion radiotherapy for residual disease
• NCT06311968 - Postoperative proton radiotherapy
• NCT06402708 - Postoperative adjuvant chemotherapy for thymic cancer

Neoadjuvant / Pre-Surgery

• NCT06924619 - Neoadjuvant radiotherapy for locally advanced unresectable thymoma
• NCT07479628 - Neoadjuvant adebrelimab + chemoRT for locally advanced thymic carcinoma (Phase 2)
• NCT07463313 - 6 vs 3 cycles neoadjuvant chemo for resectable locally advanced thymic (Phase 2/3)

Trials by Treatment Approach

Radiotherapy (14 trials)

Proton therapy and carbon ion radiotherapy offer precise tumor targeting with less damage to surrounding tissue. View all →

Chemotherapy (8 trials)

Platinum-based combinations remain a backbone of treatment for advanced disease. View all →

Checkpoint Inhibitors (4 trials)

PD-1 inhibitors show activity but require careful monitoring due to autoimmune risks (myasthenia gravis). View all →

Frequently Asked Questions